A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
Sponsored by Agouron Pharmaceuticals
About this trial
Last updated 20 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 24 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Are HIV positive.
- Are at least 18 years old.
- Are currently taking an NNRTI and at least 1 NRTI for at least 28 days and failing that therapy. (Patients who began an NRTI therapy without an NNRTI and then added an NNRTI may also enroll.)
- Are on the current NNRTI plus NRTI therapy at the time of the screening visit.
- Have a CD4 count greater than 50/mm3 and viral load greater than 2,000 copies/ml at the screening visit.
- Have adequate blood, kidney, and liver functions.
- Agree to use a barrier method of birth control while on the study.
- Agree to use additional methods of birth control if less than 2 years postmenopausal.
Exclusion Criteria
- Are using or have received other investigative drugs within 28 days of receiving the first dose of study drug.
- Are using or have received any medications or radiation treatments that interfere with the study drug within 28 days of receiving the first dose of study drug.
- Have had prior treatment with capravirine or any protease inhibitors.
- Are pregnant or breast-feeding.
- Have an active infection or serious medical condition.
- Have a mental, social, or addictive disorder that may interfere with study treatment.